Royalty Pharma PLC (RPRX)
| Market Cap | 25.42B |
| Revenue (ttm) | 2.12B |
| Net Income (ttm) | 975.04M |
| Shares Out | 375.44M |
| EPS (ttm) | 1.32 |
| PE Ratio | 31.82 |
| Forward PE | 15.70 |
| Dividend | $0.68 |
| Dividend Yield | 1.62% |
| Trading Day | April 19 |
| Last Price | $42.01 |
| Previous Close | $41.87 |
| Change ($) | 0.14 |
| Change (%) | 0.32% |
| Day's Open | 41.97 |
| Day's Range | 41.62 - 42.37 |
| Day's Volume | 460,777 |
| 52-Week Range | 34.55 - 55.87 |
NEW YORK, April 15, 2021 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2021 of $0.17 per class A share.
SYF vs. RPRX: Which Stock Is the Better Value Option?
Royalty Pharma plc (NASDAQ: RPRX) has acquired Dicerna Pharmaceuticals Inc's (NASDAQ: DRNA) royalty interest in Oxlumo (lumasiran) for an upfront cash payment of $180 million and up to $60 million in c...
NEW YORK and LEXINGTON, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) (“Royalty Pharma”) and Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Dicerna”) today announced that R...
Royalty Pharma Plc (NASDAQ: RPRX) has acquired a royalty interest in Cabometyx and Cometriq from GlaxoSmithKline Plc (NYSE: GSK) for an upfront payment of $342 million. Under this transaction's terms, R...
NEW YORK, April 01, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in the cabozantinib products Cabometyx and Cometriq from GlaxoSmith...
SYF vs. RPRX: Which Stock Is the Better Value Option?
Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Returning buyers and chief executives were among the insiders making purchases this week.
CIXX vs. RPRX: Which Stock Is the Better Value Option?
The company's royalties revenue soared, but its earnings sank.
NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter of 2020 and introduced full-year 2021 guidance for Adjusted Cash Rec...
NEW YORK, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter 2020 financial results on Wednesday, February 17, 2021 before the U.S...
NEW YORK and WALTHAM, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Minerva Neurosciences, Inc. (Nasdaq: NERV) today announced that Royalty Pharma will acquire Minerva's...
Royalty Pharma plc said Friday its board has approved a 13% increase in its quarterly dividend to 17 cents a share. The dividend will be paid March 15 to shareholders of record as of Feb. 19.
NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2021 of $0.17 per class A share...
NEW YORK, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that management will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 20...
NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced charitable contributions totaling $7,660,000 to support important COVID-19 research at The Rockefeller Unive...
NEW YORK, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an expansion of its leadership team:
NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma (Nasdaq: RPRX), BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and Athyrium Capital Management, LP today announ...
Royalty Pharma invests in biopharmaceutical royalty streams and has deployed $18bn of capital into the space since 1996 - ~50% of all deployed capital. Its portfolio of assets includes royalties from Ab...
Royalty Pharma plc (RPRX) CEO Pablo Legorreta on Q3 2020 Results - Earnings Call Transcript
NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2020 and updated full-year 2020 guidance for Adjusted Cash Receipt...
Some of the drugs under Royalty Pharma's (RPRX) royalty acquisition agreements performed well during the third quarter while others declined or flatlined.
NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement to acquire the residual royalty interest in Vertex Pharmaceuticals, Inc.'s cystic fibrosis (CF)...
Investing in biotech stocks may feel daunting to many investors, but these three stocks deserve to be on your watchlist. The post 3 Biotech Stocks With Eye-Catching Pipelines appeared first on InvestorP...
NEW YORK, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today the closing of the secondary offering of 17,343,037 shares of its Class A ordinary shares by...
NEW YORK, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma (Nasdaq: RPRX) today announced that it will report its third quarter 2020 financial results on Wednesday, November 11, 2020 before the U.S. fin...
NEW YORK, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today the pricing of the secondary offering of 17,343,037 shares of its Class A ordinary shares by...
NEW YORK, Oct. 15, 2020 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2020 of $0.15 per class A share.
NEW YORK, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today that certain selling shareholders intend to offer an aggregate 17,343,037 of the Company's C...
Although markets have pulled back so far in September, many are viewing this as a technical correction, as the markets ran very hot in a very strong August.
Royalty Pharma Discounted Despite High ROIC Business Model
NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has closed an offering of $6 billion senior unsecured notes, comprised of the following tranches ...
2020 is looking a whole lot like 1999, as technology initial public offerings that made little or no money came out and rocketed higher.
Royalty Pharma stock has faded after rallying immediately after its IPO. With valuation more reasonable, RPRX has a solid long-term case.
You'll have a rare chance to capitalize on two highly lucrative markets as Royalty Pharma stock profits from drugmakers in a different way. The post Royalty Pharma Is the Left-Field Investment You’re Mi...
Royalty Pharma PLC RPRX, +1.81% priced a $6 billion bond offering on Tuesday, joining the many companies issuing record levels of debt during the pandemic.
NEW YORK, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc announced today that it has priced an offering of $6 billion senior unsecured notes, comprised of the following tranches (collectively, t...
Royalty Pharma's cash flow growth will power the stock higher. If cash flow continues at this pace, RPRX stock could rise by at least 88% over the next three years.
NEW YORK, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc announced today that it intends to offer, subject to market and other conditions, senior unsecured notes in multiple tranches (the “Notes...
Royalty Pharma - Starting To Look More Compelling
Royalty Pharma plc (RPRX) CEO Pablo Legorreta on Q2 2020 Results - Earnings Call Transcript
Royalty Pharma PLC (NASDAQ: RPRX) had a big initial public offering this summer, and it also reported earnings on Wednesday morning.
NEW YORK, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2020 and introduced full-year 2020 guidance for Adjusted Cash R...
Biohaven will receive up to $250 million to fund zavegepant's development in migraine and non-migraine indications
The biopharmaceutical industry has been one of the most resilient in dealing with the coronavirus pandemic.
NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma (Nasdaq: RPRX) today announced the appointments of Henry A. Fernandez and Ted W. Love, M.D. to the company's Board of Directors, effective im...
NEW YORK, July 20, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma (NASDAQ: RPRX) today announced that it will report its second quarter 2020 financial results on Wednesday, August 12, 2020, before the U.S. f...
About RPRX
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio includes royalties on approximately 45 commercial products and ... [Read more...]
| Industry Biotechnology | IPO Date Jun 16, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol RPRX |
Financial Performance
In 2020, Royalty Pharma's revenue was $2.12 billion, an increase of 16.98% compared to the previous year's $1.81 billion. Earnings were $975.04 million, a decrease of -58.48%.
Analyst Forecasts
According to 8 analysts, the average rating for Royalty Pharma stock is "Buy." The 12-month stock price forecast is 52.29, which is an increase of 24.49% from the latest price.